Algeron (cepeginterferon alfa-2b) / Biocad - LARVOL DELTA

Wound healing potential of Cystoseira/mesenchymal stem cells in immunosuppressed rats supported by overwhelming immuno-inflammatory crosstalk. (PubMed, PLoS One) - "From constructed PPI network for wound healing and further analysis through molecular docking and molecular dynamics (MD) simulation experiments suggested that cystalgerone metabolite may be responsible for the wound healing-promoting effect of Cystoseira extract...Sixteen d after immunity suppression (by 40 mg/kg hydrocortisone daily), an incision was made in the dorsal skin of the rat...Our research indicates that the primary compounds of Cystoseira holds potential wound healing therapeutic activity. Although more safety testing and clinical studies are required, the combination has great potential for regenerative medicine and could be a revolutionary advance in the healing of the wounds of immunosuppressed patients."

Journal • Preclinical • Mood Disorders • ENG • THY1

"The many therapies currently in development based on #biologicalgerontology principles provide promise for the development of a new generation of therapeutics to #prevent and #treat #alzheimerdisease @hfillit @GreenJournal @INSPIREPlatfor1 https://t.co/BRhVXirLur" (@BertrandFougere)

Alzheimer's Disease • CNS Disorders

"#somaticepitype not 1 size fits all pharmaceuticals - #BiomedicalGerontology.com" (@NBAtopshotThis)

"#biomedicalgerontology.comn https://t.co/2eC5W1wGXS" (@NBAtopshotThis)

"#FollowFriday these Tweeps: @PaganoniMDPhD @ciaswansea @PatientVoices @DeVorePremier @UoDMHN @CarebuildAtHome @AnglerMD @BarnetCarers @HenryBodkin @SchaefferCenter @samstuart87 @VisualGeron @WriterDMac @MorieSmile @dsouzamichaelc @Alzheimeric @BeccaCFarley @VindellW @cindy_wallis" (@LEAD_Coalition)

Clinical • Alzheimer's Disease • CNS Disorders

"Loved all of CS Lewis and my daughter just read Flowers for Algeron so I got to revisit that as well" (@PisaniMAP)

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. (PubMed, Ter Arkh) - "Treatment of ce-pegalpha-INF-α-2b in patients with PV and ET is highly effective - the most patients pbtained clinical and hematological responses. There were no statistically significant differences in these parameters in comparison with hydroxycarbamide and rINFα. The use of the ce-pegalpha-INF-α-2b had an acceptable safety profile. The estimated therapeutic dose should be calculated according to body weight. To reduce the frequency of hematologic AE, titration of the drug dose is required."

Journal